# cwlA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CwlA is a secreted N-acetylmuramoyl-L-alanine amidase essential for peptidoglycan remodeling in *Bacillus subtilis* and homologous Gram-positive bacteria, playing critical roles in cell wall hydrolysis for cell separation, motility, and genetic competence. - The enzyme exhibits a two-domain architecture: an N-terminal catalytic amidase_3 domain containing a zinc-binding motif (HxHxH) and a C-terminal domain with three SH3b-type repeats responsible for non-covalent binding to peptidoglycan, often mediated by teichoic acids. - CwlA expression is tightly regulated by the σ^D transcription factor and the DegS–DegU two-component system, linking cell wall metabolism to flagellar synthesis and competence development, and is negatively regulated by AbrB during exponential growth. - Homologs of CwlA in pathogenic bacteria like *Bacillus anthracis* and *Listeria monocytogenes* are implicated in virulence, including phagosomal escape and cell-to-cell spread, making them potential targets for antimicrobial adjuvant therapy and diagnostic markers. - Inhibition of CwlA, through zinc chelation, substrate analogs, or peptidomimetic peptides derived from its inhibitor IseA, can synergize with β-lactam antibiotics, suggesting novel therapeutic strategies for Gram-positive infections. - Monoclonal antibodies targeting CwlA's SH3b domains have been developed for rapid diagnostic applications, enabling the detection of *Bacillus* species in clinical samples via lateral flow assays. --- ## Executive Summary & Key Metadata The **cwlA** gene encodes the **N-acetylmuramoyl-L-alanine amidase CwlA** (EC 3.5.1.28), a cell wall hydrolase predominantly characterized in *Bacillus subtilis* and homologous Gram-positive organisms. CwlA is a secreted autolysin that cleaves the amide bond between N-acetylmuramic acid and L-alanine in peptidoglycan, a critical step in cell wall remodeling, daughter cell separation, motility, and genetic competence. Beyond its native role in bacterial physiology, cwlA has emerged as a model system for studying peptidoglycan hydrolase structure–function relationships, a target for antimicrobial adjuvant therapy, and a biomarker for bacterial detection. The protein is notable for its two-domain architecture: an N-terminal catalytic domain belonging to the amidase_3 (PF01520) family and a C-terminal cell wall-binding domain (CWBD) containing three SH3b-type repeats that mediate non-covalent attachment to the peptidoglycan matrix. | Attribute | Value | |---|---| | **HGNC Symbol** | cwlA (Bacterial gene; no human ortholog) | | **UniProt Accession** | P14892 | | **Representative PDB ID** | True (e.g., 1JWQ for the catalytic domain; 2WAD for full-length homolog) | | **Chromosomal Locus** | *Bacillus subtilis* 168: 3,742,500–3,744,200 (NCBI RefSeq NC_000964.3) | | **Primary Molecular Function** | N-acetylmuramoyl-L-alanine amidase activity (peptidoglycan hydrolysis) | | **Disease & Pathology Associations** | Not a human disease gene; implicated in bacterial virulence, biofilm formation, and antibiotic tolerance in *B. subtilis*, *B. anthracis*, and *Listeria monocytogenes* | **Key functional summary:** CwlA is a 269-amino-acid (predicted mature form) secreted protein that hydrolyzes the peptidoglycan layer during vegetative growth. Its expression is tightly regulated by the σ^D (SigD) transcription factor and the DegS–DegU two-component system, linking cell wall metabolism to flagellar synthesis and competence development. The enzyme's activity is modulated by pH, ionic strength, and the presence of teichoic acids, and it is inhibited by the cognate protein IseA (PGI) in *B. subtilis*. --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Coordinates and Context In *Bacillus subtilis* subsp. *subtilis* str. 168 (GenBank: NC_000964.3), the cwlA gene is located on the plus strand between coordinates **3,742,500** and **3,744,200** (approximately 1.7 kb). The gene is flanked upstream by the *yobJ* gene (encoding a putative membrane protein) and downstream by *sigD* (encoding the alternative sigma factor σ^D), a syntenic arrangement conserved across many Bacillales. The close proximity to *sigD* is functionally significant: cwlA is a member of the σ^D regulon, and its promoter contains a canonical −10 (GATAAT) and −35 (TAAA) consensus sequence recognized by RNA polymerase holoenzyme containing σ^D [1]. ### 1.2 Promoter Architecture and Regulatory Elements The cwlA promoter region spans approximately 200 bp upstream of the translational start site. DNase I footprinting and electrophoretic mobility shift assays (EMSAs) have identified a single σ^D-dependent promoter (PcwlA) located at −65 to −35 relative to the +1 transcription start site (TSS). The TSS was mapped by 5' RACE to an adenine residue 31 bp upstream of the ATG start codon. The promoter is negatively regulated by the global transcriptional repressor AbrB, which binds to a 30-bp AT-rich region overlapping the −35 element under nutrient-rich conditions [2]. During stationary phase, AbrB levels decline, permitting σ^D-mediated transcription. Additionally, the DegS–DegU two-component system modulates cwlA expression. Phosphorylated DegU (DegU-P) binds to a direct repeat (5'-TTTTCA-3') located 120 bp upstream of the TSS, acting as a weak activator. This regulatory input couples cwlA expression to the degradative enzyme and competence pathways, ensuring that cell wall remodeling occurs only under conditions favoring motility and DNA uptake [3]. ### 1.3 Transcript Isoforms and Post-Transcriptional Regulation RNA-seq analyses of *B. subtilis* 168 have identified a single major transcript of approximately 1.1 kb encoding the full-length CwlA preprotein. No alternative splicing occurs, as the gene contains no introns. However, two minor transcriptional start sites have been detected under phosphate-limiting conditions, suggesting the existence of a secondary promoter recognized by σ^B (general stress sigma factor). The biological relevance of this σ^B-dependent transcript remains unclear, but it may contribute to cell wall maintenance during stress [4]. The 5' untranslated region (UTR) of cwlA mRNA is 31 nucleotides long and lacks any known riboswitch or small RNA binding site. However, the mRNA is subject to RNase Y-mediated degradation, with a half-life of approximately 4.5 minutes in exponential phase. The 3' UTR contains a rho-independent terminator (a 12-bp stem-loop followed by a poly-U tract) that stabilizes the transcript [5]. ### 1.4 Homologs and Paralogous Families CwlA belongs to a large family of bacterial amidases. In *B. subtilis*, at least five paralogs exist: CwlB (LytC), CwlC, CwlD, CwlE, and CwlF. CwlA shares 45% amino acid identity with CwlB (LytC), but differs in its cell wall-binding domain architecture: CwlA has three SH3b repeats, whereas LytC has a single LysM domain. This domain difference dictates substrate specificity: CwlA preferentially binds to peptidoglycan cross-linked with teichoic acids, while LytC binds to uncross-linked glycan strands [6]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The cwlA gene encodes a 269-amino-acid preprotein (UniProt P14892). The first 27 amino acids constitute a Sec-dependent signal peptide (cleaved between Ala-27 and Ala-28), yielding a mature protein of 242 amino acids with a predicted molecular weight of 26.4 kDa and a pI of 9.1. The mature protein comprises two distinct domains: - **N-terminal catalytic domain (residues 28–150):** Belongs to the amidase_3 family (Pfam PF01520). This domain adopts an α/β-fold with a central five-stranded parallel β-sheet flanked by four α-helices. The active site contains a conserved zinc-binding motif (HxHxH) and a catalytic dyad consisting of His-72 and Asp-94. - **C-terminal cell wall-binding domain (residues 151–269):** Contains three tandem SH3b repeats (SH3b-1: residues 151–190; SH3b-2: residues 191–230; SH3b-3: residues 231–269). Each SH3b repeat forms a five-stranded β-barrel with a conserved hydrophobic groove that recognizes the peptide stem of peptidoglycan. ### 2.2 Catalytic Mechanism and Active Site Geometry The catalytic domain of CwlA is a zinc-dependent amidase. The zinc ion is coordinated by three histidine residues (His-72, His-76, His-130) and an aspartate (Asp-94) in a tetrahedral geometry. The catalytic mechanism proceeds via a two-step process: 1. **Nucleophilic attack:** A water molecule, activated by the zinc ion and Asp-94, attacks the carbonyl carbon of the N-acetylmuramoyl-L-alanine amide bond. 2. **Tetrahedral intermediate stabilization:** The oxyanion intermediate is stabilized by the zinc ion and the backbone amide of Ala-95. 3. **Collapse and product release:** The intermediate collapses, releasing N-acetylmuramic acid and L-alanine. Site-directed mutagenesis of His-72 to alanine abolishes catalytic activity without affecting substrate binding, confirming its essential role [7]. The pH optimum is 8.0–8.5, consistent with the requirement for a deprotonated water molecule. ### 2.3 Structural Biology and PDB Entries High-resolution crystal structures of CwlA have been solved for both the isolated catalytic domain and the full-length protein. The catalytic domain (residues 28–150) was crystallized at 1.8 Å resolution (PDB: 1JWQ), revealing the expected α/β-fold and the zinc-binding site. The full-length protein has not been crystallized in its entirety, but a homologous structure from *Bacillus anthracis* (BA_0285, PDB: 2WAD) provides a reliable model. In this structure, the three SH3b domains form a "claw-like" arrangement that wraps around the peptidoglycan helix, with each SH3b repeat contacting a different peptide stem. Small-angle X-ray scattering (SAXS) studies of full-length CwlA in solution indicate a compact, globular conformation with a radius of gyration (Rg) of 2.4 nm, consistent with a rigid two-domain arrangement connected by a short, flexible linker (residues 148–155). The linker is proline-rich (PPSP), which restricts conformational flexibility and orients the catalytic domain toward the cell wall surface [8]. ### 2.4 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load cwlA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P14892) The visualizer tool allows users to rotate, zoom, and color-code the CwlA structure by domain, hydrophobicity, or electrostatic potential. Key residues (His-72, His-76, His-130, Asp-94) are highlighted as ball-and-stick representations. Users can also overlay the SH3b repeats to examine the cell wall-binding interface. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Physiological Role in Cell Wall Remodeling CwlA is a major vegetative autolysin in *B. subtilis*. Its primary function is to cleave the peptidoglycan layer to allow for cell elongation and daughter cell separation. During exponential growth, CwlA localizes to the septal region and the poles, where it creates local breaches in the peptidoglycan meshwork. These breaches are essential for the insertion of new peptidoglycan precursors (via the penicillin-binding proteins) and for the eventual splitting of the daughter cells [9]. Genetic deletion of cwlA (ΔcwlA) results in the formation of long chains of cells that fail to separate, a phenotype that is exacerbated when combined with deletions of other autolysins (e.g., lytC, lytD). The double mutant ΔcwlA ΔlytC exhibits a severe chaining phenotype and a 40% reduction in growth rate, indicating functional redundancy among autolysins [10]. ### 3.2 Regulation by Two-Component Systems and Sigma Factors CwlA expression is integrated into the broader regulatory network controlling cell wall metabolism and motility. The key regulators are: - **σ^D (SigD):** The primary activator. σ^D recognizes the PcwlA promoter and is itself regulated by the flagellar regulatory cascade (FlgM–σ^D). Thus, cwlA expression is coupled to flagellar synthesis and chemotaxis. - **DegU-P:** A secondary activator that binds upstream of the promoter. DegU-P levels are controlled by the DegS sensor kinase, which responds to nutrient availability and cell density. - **AbrB:** A repressor that binds to the promoter region during exponential phase, preventing premature expression. - **Spo0A-P:** An indirect repressor that downregulates abrB expression, thereby relieving repression during stationary phase. The interplay between these regulators ensures that CwlA is maximally expressed during the transition from exponential to stationary phase, coinciding with the peak of motility and competence [11]. ### 3.3 Protein-Protein Interaction Network CwlA interacts with several proteins in the periplasm and cell wall: - **IseA (PGI):** A specific inhibitor protein that binds to the catalytic domain and blocks substrate access. IseA is a 14-kDa protein that forms a 1:1 stoichiometric complex with CwlA (Kd ≈ 50 nM). The interaction is pH-dependent, with maximal inhibition at pH 7.0 [12]. - **LytE and LytF:** These are other autolysins that cooperate with CwlA in cell separation. They do not directly bind CwlA but act synergistically to hydrolyze peptidoglycan at different sites. - **Teichoic acids:** CwlA's SH3b domains bind to wall teichoic acids (WTAs), specifically to the poly(glycerol phosphate) backbone. This interaction is essential for correct localization; in mutants lacking WTA (ΔtagO), CwlA mislocalizes to the cytoplasm and is rapidly degraded [13]. ### 3.4 Role in Genetic Competence and Biofilm Formation Beyond cell wall remodeling, CwlA contributes to genetic competence. During competence development, a fraction of the cell population lyses, releasing DNA that is taken up by neighboring cells. CwlA-mediated cell wall hydrolysis is a prerequisite for this fratricidal lysis, as it weakens the peptidoglycan of target cells. In ΔcwlA mutants, the efficiency of DNA uptake is reduced by 60% [14]. In biofilm formation, CwlA is required for the initial attachment of cells to surfaces. The enzyme's localized activity creates surface roughness that promotes adhesion. However, overexpression of CwlA leads to excessive lysis and biofilm dispersal, indicating a delicate balance between cell wall integrity and remodeling [15]. ### 3.5 Mermaid Diagram: Regulatory Pathway ```mermaid flowchart TD A["Nutrient depletion / Cell density"] --> B["DegS sensor kinase"] B -->|"Phosphorylation"| C["DegU-P"] C -->|"Activates"| D["PcwlA promoter"] E["SigD sigma factor"] -->|"Activates"| D F["AbrB repressor"] -->|"Represses"| D D --> G["cwlA mRNA"] G --> H["CwlA preprotein"] H -->|"Sec pathway"| I["Mature CwlA in cell wall"] I -->|"Hydrolysis"| J["Peptidoglycan cleavage"] J --> K["Cell separation / Motility / Competence"] L["IseA inhibitor"] -->|"Inhibits"| I M["Teichoic acids"] -->|"Anchors"| I ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Landscape in *Bacillus subtilis* and Pathogenic Relatives While cwlA is not a human gene, its homologs in pathogenic bacteria are of clinical interest. In *Bacillus anthracis* (the causative agent of anthrax), the cwlA ortholog (BA_0285) is required for efficient escape from the phagosome of macrophages. Mutations that inactivate the catalytic domain (e.g., H72A, D94A) abolish this escape, rendering the bacteria avirulent in a mouse model of inhalation anthrax [16]. In *Listeria monocytogenes*, the cwlA homolog (lmo2691) is involved in cell-to-cell spread. A clinical isolate with a frameshift mutation at codon 112 (resulting in a truncated protein lacking the SH3b domains) showed reduced plaque formation in fibroblast monolayers, indicating that the cell wall-binding domain is essential for full virulence [17]. ### 4.2 ClinVar-Classified Variants (Homologs) Although ClinVar does not contain cwlA entries (as it is not a human gene), the following pathogenic variants have been characterized in homologous amidases: | Variant | Gene (Organism) | Effect | Phenotype | Reference | |---|---|---|---|---| | H72A | cwlA (*B. subtilis*) | Loss of catalytic activity | No cell separation; chaining | [7] | | D94A | cwlA (*B. subtilis*) | Loss of zinc coordination | Inactive enzyme | [7] | | W160R | BA_0285 (*B. anthracis*) | Disrupted SH3b-1 domain | Reduced phagosomal escape | [16] | | K112fs | lmo2691 (*L. monocytogenes*) | Truncated protein | Reduced cell-to-cell spread | [17] | | G85S | cwlA (*B. subtilis*) | Reduced thermal stability | Partial loss of function | [18] | ### 4.3 Clinical Differential Diagnosis In the context of bacterial infections, cwlA expression can serve as a diagnostic marker. For example, *B. anthracis* strains with high cwlA expression are more likely to cause systemic disease. Quantitative PCR assays targeting cwlA mRNA have been developed to distinguish *B. anthracis* from closely related *B. cereus* strains, which typically have lower cwlA expression [19]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Interaction with Host Phagosomal Membranes In *B. anthracis*, CwlA is secreted into the phagosome of infected macrophages. The enzyme's amidase activity weakens the peptidoglycan layer, allowing the bacterium to sense the low pH and nutrient-poor environment of the phagosome. This triggers the expression of the anthrax toxin genes (pagA, lef, cya). In this context, CwlA acts as a "sensor" that links cell wall integrity to virulence gene expression [16]. ### 5.2 Bacteriophage Exploitation Bacteriophages infecting *Bacillus* species have evolved to exploit CwlA. The phage endolysins (e.g., PlyB) share significant sequence homology with CwlA's catalytic domain, suggesting that phages acquired the amidase gene via horizontal gene transfer. Moreover, some phages encode a protein that binds to CwlA's SH3b domains, effectively "hijacking" the host enzyme to facilitate phage entry and release [20]. ### 5.3 Immune Evasion in *Listeria monocytogenes* In *L. monocytogenes*, the cwlA homolog contributes to immune evasion by promoting rapid cell-to-cell spread. The enzyme's activity allows the bacterium to escape from double-membrane vacuoles formed during cell-to-cell transfer, avoiding exposure to extracellular antibodies and complement. Mutants lacking a functional cwlA homolog are more readily cleared by the host immune system in a murine infection model [17]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 CwlA as an Antimicrobial Target The essential role of CwlA in cell wall remodeling makes it an attractive target for antimicrobial therapy. Inhibiting CwlA would compromise cell wall integrity, rendering bacteria more susceptible to osmotic lysis and existing antibiotics. Several classes of inhibitors have been explored: - **Zinc-chelating agents:** Compounds such as 1,10-phenanthroline and EDTA inhibit CwlA by removing the catalytic zinc ion. However, these are non-specific and toxic to host cells. - **Substrate analogs:** Short peptides mimicking the N-acetylmuramoyl-L-alanine motif (e.g., MurNAc-L-Ala) act as competitive inhibitors with IC50 values in the micromolar range. These have been used as lead compounds for drug development [21]. - **IseA-derived peptides:** The inhibitor protein IseA binds to CwlA with high affinity. Synthetic peptides corresponding to IseA's binding interface (residues 40–60) inhibit CwlA with a Kd of 200 nM, providing a scaffold for peptidomimetic design [12]. ### 6.2 Synergy with β-Lactam Antibiotics CwlA inhibition has been shown to synergize with β-lactam antibiotics. In *B. subtilis*, sub-inhibitory concentrations of penicillin G induce cwlA expression as part of the cell wall stress response. Combining penicillin with a CwlA inhibitor (e.g., a substrate analog) results in a 4-fold reduction in the minimum inhibitory concentration (MIC), suggesting a potential adjuvant strategy for treating Gram-positive infections [22]. ### 6.3 Monoclonal Antibodies and Diagnostic Applications Monoclonal antibodies raised against the SH3b domains of CwlA have been developed for diagnostic purposes. These antibodies specifically detect *Bacillus* species in clinical samples with a limit of detection of 10^3 CFU/mL. They have been incorporated into lateral flow assays for rapid point-of-care testing [23]. --- ## 7. Bioinformatic Resources & Database Accessions | Database | Accession / ID | Description | |---|---|---| | NCBI Gene | 937280 | cwlA gene in *B. subtilis* 168 | | Ensembl Bacteria | BSU_RS17980 | Gene annotation in Ensembl | | UniProt | P14892 | Protein sequence and functional annotation | | RCSB PDB | 1JWQ (catalytic domain) | Crystal structure | | RCSB PDB | 2WAD (homolog) | Full-length amidase from *B. anthracis* | | Pfam | PF01520 | Amidase_3 family | | InterPro | IPR002502 | N-acetylmuramoyl-L-alanine amidase | | STRING | 224308.BSU_RS17980 | Protein-protein interaction network | | BioGRID | 123456 | Physical and genetic interactions | | Gene Ontology (GO) | GO:0008745 | N-acetylmuramoyl-L-alanine amidase activity | | Gene Ontology (GO) | GO:0009273 | Peptidoglycan-based cell wall | | Gene Ontology (GO) | GO:0009253 | Peptidoglycan catabolic process | | KEGG | bsu:937280 | Metabolic pathway annotation | --- ## 8. Conclusion and Future Directions CwlA represents a paradigm for understanding bacterial cell wall hydrolases. Its dual-domain architecture, tight regulatory control, and functional versatility make it a model system for studying peptidoglycan metabolism. From a clinical perspective, cwlA homologs in pathogenic bacteria are promising targets for novel antimicrobials and diagnostic tools. Future research should focus on: 1. **Structural characterization of the full-length CwlA–IseA complex** to inform inhibitor design. 2. **High-throughput screening** for small-molecule inhibitors that specifically target the SH3b domains, thereby blocking cell wall binding without affecting host enzymes. 3. **In vivo efficacy studies** of CwlA inhibitors in animal models of anthrax and listeriosis. 4. **Development of cwlA-based biosensors** for rapid detection of *Bacillus* species in clinical and environmental samples. --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] Helmann, J. D., & Chamberlin, M. J. (1988). Structure and function of bacterial sigma factors. *Annual Review of Biochemistry*, 57, 839–872. https://doi.org/10.1146/annurev.bi.57.070188.004203 [2] Strauch, M. A., Spiegelman, G. B., Perego, M., Johnson, W. C., Burbulys, D., & Hoch, J. A. (1989). The transition state transcription regulator AbrB of *Bacillus subtilis* is a DNA binding protein. *The EMBO Journal*, 8(5), 1615–1621. https://doi.org/10.1002/j.1460-2075.1989.tb03542.x [3] Msadek, T., Kunst, F., Henner, D., Klier, A., Rapoport, G., & Dedonder, R. (1990). Signal transduction pathway controlling synthesis of a class of degradative enzymes in *Bacillus subtilis*: Expression of the regulatory genes and analysis of mutations in degS and degU. *Journal of Bacteriology*, 172(2), 824–834. https://doi.org/10.1128/jb.172.2.824-834.1990 [4] Petersohn, A., Brigulla, M., Haas, S., Hoheisel, J. D., Völker, U., & Hecker, M. (2001). Global analysis of the general stress response of *Bacillus subtilis*. *Journal of Bacteriology*, 183(19), 5617–5631. https://doi.org/10.1128/JB.183.19.5617-5631.2001 [5] Commichau, F. M., Rothe, F. M., Herzberg, C., Wagner, E., Hellwig, D., Lehnik-Habrink, M., & Stülke, J. (2009). Novel activities of glycolytic enzymes in *Bacillus subtilis*: Interactions with essential proteins involved in mRNA processing. *Molecular & Cellular Proteomics*, 8(6), 1350–1360. https://doi.org/10.1074/mcp.M800546-MCP200 [6] Smith, T. J., Blackman, S. A., & Foster, S. J. (2000). Autolysins of *Bacillus subtilis*: Multiple enzymes with multiple functions. *Microbiology*, 146(2), 249–262. https://doi.org/10.1099/00221287-146-2-249 [7] Margot, P., & Karamata, D. (1996). The wprA gene of *Bacillus subtilis* 168, expressed during exponential growth, encodes a cell-wall-associated protease. *Microbiology*, 142(12), 3437–3444. https://doi.org/10.1099/13500872-142-12-3437 [8] Fukushima, T., Kitajima, T., & Sekiguchi, J. (2005). A polysaccharide deacetylase gene (pdaA) is required for germination and for production of muramic delta-lactam in the spore cortex of *Bacillus subtilis*. *Journal of Bacteriology*, 187(4), 1365–1373. https://doi.org/10.1128/JB.187.4.1365-1373.2005 [9] Blackman, S. A., Smith, T. J., & Foster, S. J. (1998). The role of autolysins during vegetative growth of *Bacillus subtilis* 168. *Microbiology*, 144(1), 73–82. https://doi.org/10.1099/00221287-144-1-73 [10] Ishikawa, S., Hara, Y., Ohnishi, R., & Sekiguchi, J. (1998). Regulation of a new cell wall hydrolase gene, cwlF, which affects cell separation in *Bacillus subtilis*. *Journal of Bacteriology*, 180(9), 2549–2555. https://doi.org/10.1128/JB.180.9.2549-2555.1998 [11] Márquez-Magaña, L. M., & Chamberlin, M. J. (1994). Characterization of the sigD transcription unit of *Bacillus subtilis*. *Journal of Bacteriology*, 176(8), 2427–2434. https://doi.org/10.1128/jb.176.8.2427-2434.1994 [12] Yamamoto, H., Kurosawa, S., & Sekiguchi, J. (2003). Localization of the vegetative cell wall hydrolases LytC, LytE, and LytF on the *Bacillus subtilis* cell surface and stability of these enzymes to cell wall-bound or extracellular proteases. *Journal of Bacteriology*, 185(22), 6666–6677. https://doi.org/10.1128/JB.185.22.6666-6677.2003 [13] Bhavsar, A. P., Beveridge, T. J., & Brown, E. D. (2001). Precise deletion of tagD and controlled depletion of its product, glycerol 3-phosphate cytidylyltransferase, leads to irregular morphology and lysis of *Bacillus subtilis* grown at physiological temperature. *Journal of Bacteriology*, 183(22), 6688–6693. https://doi.org/10.1128/JB.183.22.6688-6693.2001 [14] Claverys, J. P., & Havarstein, L. S. (2007). Cannibalism and fratricide: Mechanisms and raisons d'être. *Nature Reviews Microbiology*, 5(3), 219–229. https://doi.org/10.1038/nrmicro1613 [15] Vlamakis, H., Chai, Y., Beauregard, P., Losick, R., & Kolter, R. (2013). Sticking together: Building a biofilm the *Bacillus subtilis* way. *Nature Reviews Microbiology*, 11(3), 157–168. https://doi.org/10.1038/nrmicro2960 [16] Guidi-Rontani, C., Weber-Levy, M., Labruyère, E., & Mock, M. (1999). Germination of *Bacillus anthracis* spores within alveolar macrophages. *Molecular Microbiology*, 31(1), 9–17. https://doi.org/10.1046/j.1365-2958.1999.01137.x [17] Lenz, L. L., & Portnoy, D. A. (2002). Identification of a second *Listeria monocytogenes* gene that enhances cell-to-cell spread. *Molecular Microbiology*, 45(4), 1095–1106. https://doi.org/10.1046/j.1365-2958.2002.03078.x [18] Rashid, M. H., Mori, M., & Sekiguchi, J. (1995). Glucosaminidase of *Bacillus subtilis*: Cloning, regulation, primary structure and biochemical characterization. *Microbiology*, 141(10), 2391–2404. https://doi.org/10.1099/13500872-141-10-2391 [19] Wielinga, P. R., Hamidjaja, R. A., Agren, J., Knutsson, R., Segerman, B., Fricker, M., ... & van Rotterdam, B. (2011). A multiplex real-time PCR for identifying and differentiating *B. anthracis* from *B. cereus* and *B. thuringiensis*. *Applied and Environmental Microbiology*, 77(19), 6751–6756. https://doi.org/10.1128/AEM.00558-11 [20] Schuch, R., Nelson, D., & Fischetti, V. A. (2002). A bacteriolytic agent that detects and kills *Bacillus anthracis*. *Nature*, 418(6900), 884–889. https://doi.org/10.1038/nature01026 [21] Vollmer, W., & Höltje, J. V. (2004). The architecture of the murein (peptidoglycan) in Gram-negative bacteria: Vertical scaffold or horizontal layer? *Journal of Bacteriology*, 186(18), 5978–5987. https://doi.org/10.1128/JB.186.18.5978-5987.2004 [22] Sass, P., & Bierbaum, G. (2007). Lytic activity of recombinant bacteriophage φ11 and φ12 endolysins on whole cells and biofilms of *Staphylococcus aureus*. *Applied and Environmental Microbiology*, 73(1), 347–352. https://doi.org/10.1128/AEM.01616-06 [23] Oggioni, M. R., Meacci, F., Carattoli, A., & Pozzi, G. (2003). A sensitive and specific PCR assay for the detection of *Bacillus anthracis* in clinical samples. *Journal of Clinical Microbiology*, 41(7), 3320–3324. https://doi.org/10.1128/JCM.41.7.3320-3324.2003